Overview of Class Action Notice for Regeneron Pharmaceuticals Shareholders
The Gross Law Firm has issued an important notification aimed at shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). If you purchased shares within the specified class period, you should reach out to the firm promptly to understand your legal rights and options for possible participation in a class action lawsuit.
Who Should Reach Out?
Shareholders who acquired shares of REGN during the designated timeframe are strongly encouraged to contact the Gross Law Firm. Engaging with the firm provides insights on the potential for lead plaintiff appointment, which, while beneficial, is not necessary for any recovery related to the allegations stated.
Class Period Details
The class period runs from November 2, 2023, to October 30, 2024. This timeframe is critical for determining eligibility for participation in the lawsuit.
Allegations Against Regeneron Pharmaceuticals
The allegations made against Regeneron encompass various misleading assertions that were allegedly made during the class period. Key points include:
- Regeneron is accused of making payments to distributors for credit card fees, which were meant to prevent distributors from charging higher prices to customers purchasing the company's primary product, Eylea, with credit cards.
- This practice purportedly allowed Regeneron to subsidize prices, providing an unfair advantage in the market.
- The company has been charged with misleadingly inflating reported sales figures of Eylea.
- Furthermore, it is claimed that Regeneron's failure to report these credit card fee payments as price concessions constituted a violation of the False Claims Act.
- These actions allegedly resulted in misrepresentations regarding the company’s business performance and prospects, which could have impacted shareholder decisions.
Actions Required by Shareholders
It is crucial for shareholders to register without delay for participation in this class action. The official deadline for registration and to express interest in potentially becoming a lead plaintiff is March 10, 2025. Engaging now helps in ensuring you are included in future communications regarding this case.
Next Steps for Shareholders Involved
Upon registering with the Gross Law Firm as a shareholder who purchased shares of REGN in the specified timeframe, you will become part of a portfolio monitoring system. This service will keep you informed about the progress of your case and any relevant developments. Remember, there is no obligation or cost associated with this engagement, enabling you to make informed decisions about your rights and potential recovery avenues.
The Role of the Gross Law Firm
The Gross Law Firm stands as a respected entity known for its dedication to protecting investors' rights. The firm’s primary mission revolves around ensuring that investors are not subject to deception or illegal business practices. By focusing on responsible corporate behavior and advocating for transparent operations, the Gross Law Firm strives for justice for affected shareholders.
Contact Information
For questions or to initiate the registration process, shareholders may reach out to the Gross Law Firm directly:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Phone: (646) 453-8903
Frequently Asked Questions
1. What is the purpose of the class action notice?
The notice informs shareholders about their rights regarding possible participation in a class action lawsuit against Regeneron Pharmaceuticals due to alleged misleading practices.
2. How can I register for the class action?
Shareholders can follow the registration process outlined by the Gross Law Firm to become involved in the case.
3. Who qualifies to participate in the lawsuit?
Any shareholder who purchased shares of REGN within the specified class period is eligible to consider joining the lawsuit.
4. What are the risks of participating in the class action?
There is no cost or obligation involved for shareholders who choose to register, making participation a low-risk option to protect their rights.
5. What can shareholders expect after registering?
Registered shareholders will receive updates regarding their case status and any important developments throughout the litigation process.
